[go: up one dir, main page]

PE20061396A1 - Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib - Google Patents

Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib

Info

Publication number
PE20061396A1
PE20061396A1 PE2006000400A PE2006000400A PE20061396A1 PE 20061396 A1 PE20061396 A1 PE 20061396A1 PE 2006000400 A PE2006000400 A PE 2006000400A PE 2006000400 A PE2006000400 A PE 2006000400A PE 20061396 A1 PE20061396 A1 PE 20061396A1
Authority
PE
Peru
Prior art keywords
egfr
gefitinib
growth factor
factor receptor
kinase inhibitors
Prior art date
Application number
PE2006000400A
Other languages
English (en)
Inventor
Charles M Zacharchuk
Susan E Quinn
Lee Greenberger
Ante Bill Lundberg
Patricia Martins
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20061396A1 publication Critical patent/PE20061396A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A UNA COMBINACION FARMACEUTICA QUE COMPRENDE: a) GEFINITIB O IRESSA, SOLO O EN COMBINACION CON OTROS AGENTES CITOTOXICOS O AGENTES QUIMIOTERAPEUTICOS, Y b) UN INHIBIDOR DE QUINASA DEL EGFR. DICHO INHIBIDOR DE EGFR ES UN COMPUESTO DE FORMULA 1, DONDE X ES CICLOALQUILO C3-C7, PIRIDINILO, PIRIMIDINILO, ENTRE OTROS; n ES 0 O 1; Y ES NH, O, S O NR; R ES ALQUILO C1-C6; R1, R2, R3 Y R4 SON H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS DE FORMULA 1 PREFERIDOS: ([4-(3-CLORO-4-FLUOR-FENILAMINO)-3-CIANO-7-ETOXI-QUINOLIN-6-IL]-AMIDA DE ACIDO 4-DIMETILAMINO-BUT-2-ENOICO, ((E)-N-{4-[3-CLORO-4-(2-PIRIDINILMETOXI)ANILIN]-3-CIANO-7-ETOXI-6-QUINOLINIL}-4-(DIMETILAMINO)-2-BUTENAMIDA, ENTRE OTROS. DICHA COMBINACION ES UTIL PARA TRATAR O INHIBIR CANCER EN UN HUMANO QUE TIENE AL MENOS UNO DE UNA DELECION DEL EXON 19 E746-A750 Y/O UNA MUTACION PUNTUAL EN EL EXON 21
PE2006000400A 2005-04-14 2006-04-17 Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib PE20061396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67128705P 2005-04-14 2005-04-14

Publications (1)

Publication Number Publication Date
PE20061396A1 true PE20061396A1 (es) 2007-01-12

Family

ID=36791648

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000400A PE20061396A1 (es) 2005-04-14 2006-04-17 Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib

Country Status (19)

Country Link
US (1) US20060235046A1 (es)
EP (1) EP1871371A2 (es)
JP (1) JP2008536847A (es)
KR (1) KR20080002826A (es)
CN (1) CN101160129A (es)
AR (1) AR053357A1 (es)
AU (1) AU2006236940A1 (es)
BR (1) BRPI0610574A2 (es)
CA (1) CA2646257A1 (es)
CR (1) CR9415A (es)
GT (1) GT200600146A (es)
IL (1) IL186302A0 (es)
MX (1) MX2007012662A (es)
NO (1) NO20074722L (es)
PE (1) PE20061396A1 (es)
RU (1) RU2007134908A (es)
TW (1) TW200718421A (es)
WO (1) WO2006113151A2 (es)
ZA (1) ZA200708755B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2958968T3 (es) 2008-06-17 2024-02-16 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
SG10202102855RA (en) 2008-08-04 2021-05-28 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
US20100185419A1 (en) * 2008-09-05 2010-07-22 Avila Therapeutics, Inc. Algorithm for designing irreversible inhibitors
WO2010086382A1 (en) * 2009-01-30 2010-08-05 Pronota N.V. Target for treatment of acute heart failure
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
NZ598705A (en) * 2009-09-16 2014-06-27 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
US9364469B1 (en) * 2015-08-26 2016-06-14 Macau University Of Science And Technology Identification of a new AMPK activator for treatment of lung cancer
AU2019340366B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2005018677A2 (en) * 2003-08-01 2005-03-03 Wyeth Holdings Corporation Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
US7399865B2 (en) * 2003-09-15 2008-07-15 Wyeth Protein tyrosine kinase enzyme inhibitors
SI1733056T1 (sl) * 2004-03-31 2013-10-30 The General Hospital Corporation Postopek določanja odzivnosti rakaste tvorbe na zdravljenje, kjer je tarča receptor epidermalnega rastnega faktorja
MX2007009317A (es) * 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.

Also Published As

Publication number Publication date
WO2006113151A2 (en) 2006-10-26
CN101160129A (zh) 2008-04-09
EP1871371A2 (en) 2008-01-02
JP2008536847A (ja) 2008-09-11
RU2007134908A (ru) 2009-05-20
AR053357A1 (es) 2007-05-02
CA2646257A1 (en) 2006-10-26
CR9415A (es) 2008-01-21
NO20074722L (no) 2007-11-12
KR20080002826A (ko) 2008-01-04
AU2006236940A1 (en) 2006-10-26
TW200718421A (en) 2007-05-16
WO2006113151A3 (en) 2007-01-11
ZA200708755B (en) 2008-10-29
MX2007012662A (es) 2008-04-04
BRPI0610574A2 (pt) 2010-07-06
GT200600146A (es) 2006-11-07
IL186302A0 (en) 2008-08-07
US20060235046A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
PE20061396A1 (es) Inhibidores de quinasa del receptor del factor de crecimiento epidermico (egfr) en pacientes resistentes a gefitinib
SG154435A1 (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
ATE456565T1 (de) Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
NO20062763L (no) Pyrrolotriazinforbindelser som kinaseinhibitorer
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
MX2008011123A (es) Benzotiazoles que tienen actividad de receptor h3 de histamina.
NO20070529L (no) Kinazolindionderivater som parp-inhibitorer
MY147780A (en) Carboxamide compounds and their use as calpain inhibitors
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
AR061302A1 (es) Metodo para mejoramiento de funcion cognitiva
PE20060681A1 (es) Composicion farmaceutica que comprende un inhibidor de tace en combinacion con un inhibidor de quinasa de src y un inhibidor del her-2
MY148988A (en) Terphenyl derivatives for treatment of alzheimer's disease
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
GT200600105A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
DE602005023124D1 (de) Spirobenzodioxole und deren verwendung als cb1-antagonisten
DE60306546D1 (de) Entzündungshemmende 3-arylthio-3-thiazolylalkylamine
MY139522A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
SE0302756D0 (sv) Novel Compounds
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.

Legal Events

Date Code Title Description
FC Refusal